A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)

PURPOSE: Lenvatinib is an oral multi-targeted tyrosine kinase inhibitor of VEGFR1-3, FGFR1-4, PDGFRβ, RET, and KIT. Everolimus is an oral mammalian target of rapamycin inhibitor approved for advanced renal cell carcinoma (RCC). This phase 1b study assessed safety, maximum tolerated dose (MTD), and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Molina, Ana M., Hutson, Thomas E., Larkin, James, Gold, Anne M., Wood, Karen, Carter, Dave, Motzer, Robert, Michaelson, M. Dror
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889692/
https://www.ncbi.nlm.nih.gov/pubmed/24190702
http://dx.doi.org/10.1007/s00280-013-2339-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889692/
https://www.ncbi.nlm.nih.gov/pubmed/24190702
http://dx.doi.org/10.1007/s00280-013-2339-y

Ejemplares similares